Rein Therapeutics (NASDAQ:RNTX) Director Purchases $24,581.40 in Stock

Rein Therapeutics Inc. (NASDAQ:RNTX) Director Rickenbach Josef Von purchased 23,190 shares of Rein Therapeutics stock in a transaction dated Tuesday, May 26th. The shares were acquired at an average cost of $1.06 per share, for a total transaction of $24,581.40. Following the transaction, the director directly owned 58,014 shares of the company’s stock, valued at approximately $61,494.84. This represents a 66.59% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Rein Therapeutics Stock Up 4.7%

Shares of RNTX traded up $0.05 during mid-day trading on Thursday, hitting $1.11. 425,172 shares of the company’s stock were exchanged, compared to its average volume of 1,491,003. Rein Therapeutics Inc. has a fifty-two week low of $0.95 and a fifty-two week high of $2.18. The stock’s 50-day moving average is $1.33 and its 200-day moving average is $1.31.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.30. Analysts forecast that Rein Therapeutics Inc. will post -1.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP purchased a new position in Rein Therapeutics in the third quarter worth approximately $35,000. HRT Financial LP purchased a new position in Rein Therapeutics in the fourth quarter worth approximately $38,000. Chicago Partners Investment Group LLC lifted its stake in Rein Therapeutics by 32.2% in the first quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after acquiring an additional 10,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in Rein Therapeutics in the second quarter worth approximately $68,000. Finally, Jane Street Group LLC purchased a new position in Rein Therapeutics in the fourth quarter worth approximately $72,000. Hedge funds and other institutional investors own 90.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Rein Therapeutics to a “sell” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Rein Therapeutics presently has an average rating of “Hold” and an average price target of $8.00.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.